Endokrine Hypertonie – Neuigkeiten und jüngste Entwicklungen

Schlüsselwörter

Hypertonie - endokrine Hypertonie - Nebenniere - Aldosteron - Cortisol - Phäochromozytom

Keywords

hypertension - endocrine hypertension - adrenal - aldosterone - cortisol - pheochromocytoma

• Literatur

• 1 Ahmed AH, Calvird M, Gordon RD et al. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab 2011; 96: 1039-1045
• 2 Ahmed AH, Gordon RD, Sukor N et al. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96: 2904-2911
• 3 Amar L, Azizi M, Menard J et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010; 56: 831-838
• 4 Azizan EA, Murthy M, Stowasser M et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; in press
• 5 Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362: 590-599
• 6 Biller BM, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008; 93: 2454-2462
• 7 Boulkroun S, Beuschlein F, Rossi GP et al. Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension 2012; In Press
• 8 Burton TJ, Mackenzie IS, Balan K et al. Evaluation of the Sensitivity and specificity of 11C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. J Clin Endocrinol Metab 2012; 97: 100-109
• 9 Calhoun DA, White WB, Krum H et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension. Circulation 2011; 124: 1945-1955
• 10 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-36
• 11 Choi M, Scholl UI, Yue P et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
• 12 Chopra S, Cherian D, Jacob JJ. The thyroid hormone, parathyroid hormone and vitamin D associated hypertension. Indian J Endocrinol Metab 2011; 15S4: 354-360
• 13 Eisenhofer G, Lenders JW, Timmers H et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011; 57: 411-420
• 14 Elamin MB, Murad MH, Mullan R et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93: 1553-1562
• 15 Fallo F, Bertello C, Tizzani D et al. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. J Hypertens 2011; 29: 1773-1777
• 16 Feelders RA, de Bruin C, Pereira AM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362: 1846-1848
• 17 Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 18 Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 19 Schmiemann G, Gebhardt K, Hummers-Pradier E et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98-103
• 20 Späth M, Korovkin S, Antke C et al. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol 2011; 164: 447-455
• 21 Steffensen C, Bak AM, Rubeck KZ et al. Epidemiology of Cushing's syndrome. Neuroendocrinology 2010; 92 (Suppl. 01) 1-5
• 22 Steichen O, Blanchard A, Plouin PF. Assessment of serum sodium to urinary sodium divided by (serum potassium)2 to urinary potassium as a screening tool for primary aldosteronism. Eur J Clin Invest 2011; 41: 189-194
• 23 Swearingen B, Wu N, Chen SY et al. Health care resource use and costs among patients with cushing disease. Endocr Pract 2011; 17: 681-690
• 24 Tomaschitz A, Maerz W, Pilz S et al. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol 2010; 55: 2171-2180
• 25 Tomaschitz A, Pilz S, Ritz E et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31: 1237-1247
• 26 Tritos NA, Biller BM, Swearingen B. Medscape. Management of Cushing disease. Nat Rev Endocrinol 2011; 7: 279-289
• 27 Valassi E, Santos A, Yaneva M et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165: 383-392
• 28 Willenberg HS, Kolentini C, Quinkler M et al. The serum sodium to urinary sodium to (serum potassium) 2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest 2009; 39: 43-50
• 29 Coalo A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of pasireotide in Cushing's disease. New Engl J Med 2012; 366: 354-360